Conditions: Ovarian Neoplasms
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 58
Healthy volunteers: no

Brief summary:
The aim of this study is to evaluate efficacy and tolerability, and number of positive response to treatment with CAELYX (50 mg/m\^2), administered as monotherapy once per 4 weeks to patients with metastatic epithelial ovarian cancer, resistant to previous platinum therapy.

Detailed description:

Arms:
arm 1: Caelyx Intravenous, 50 mg/m\^2, given for 6 cycles

Interventions: intervention 1: Pegylated Liposomal Doxorubicin hydrochloride
Intervention descriptions: intervention 1: Caelyx Intravenous, 50 mg/m\^2 (60 minute infusion) on day 1, every 4 weeks, during 6 cycles

Protocol document: